Opaleye Management
Opaleye Management reported 58 stocks worth $1.1B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are LQDA (17.7%), ETON (9.4%) and HROW (9.2%). Compared with Q1 2026, the fund opened new positions in IMMX, GLUE and REPL, added to IRON, URGN and MGTX, trimmed LQDA, HROW and RYTM and sold out of CATX, STRO and TECX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  LQDA Liquidia Corporation | $195M | 17.7% | 2.4M | −98K (−4%) | 8 of 8 | |
| 2 |  ETON Eton Pharmaceuticals Inc | $104M | 9.4% | 2.9M | No change | 8 of 8 | |
| 3 |  HROW Harrow Inc | $102M | 9.2% | 2.4M | −432K (−15%) | 8 of 8 | |
| 4 |  IRON Disc Medicine Inc | $62.5M | 5.7% | 855K | +434K (+103%) | 6 of 8 | |
| 5 |  URGN Urogen Pharma Ltd | $53M | 4.8% | 1.4M | +9,996 (+1%) | 5 of 8 | |
| 6 | APOGEE THERAPEUTICS INC | $51.8M | 4.7% | 390K | No change | 4 of 8 | |
| 7 |  MGTX Meiragtx Hldgs PLC | $48M | 4.3% | 3.5M | +1.4M (+67%) | 3 of 8 | |
| 8 |  SLGL Sol Gel Technologies | $37.1M | 3.4% | 500K | No change | 4 of 8 | |
| 9 |  RZLT Rezolute Inc | $32.8M | 3.0% | 6.3M | No change | 8 of 8 | |
| 10 |  TGTX TG Therapeutics Inc | $29.4M | 2.7% | 535K | No change | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 CATX Perspective Therapeutics Inc | $19.5M | 4.7M |
ASSERTIO HLDGS INC | $5.1M | 266K |
 STRO Sutro Biopharma Inc | $4.7M | 191K |
 TECX Tectonic Therapeutic Inc | $3.8M | 123K |
 RIGL Rigel Pharmaceuticals Inc | $1.9M | 70K |
🔒 Free account: see all 9.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Opaleye Management 13F FAQ
What does Opaleye Management own?
Opaleye Management reported 58 stocks worth $1.1B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are LQDA (17.7%), ETON (9.4%) and HROW (9.2%). The table above lists every position in the filing (the top 10 without an account).
What did Opaleye Management buy and sell in Q2 2026?
Compared with Q1 2026: 13 new positions, 15 added to, 13 trimmed and 9 sold out. New positions include IMMX, GLUE and REPL. It sold all of CATX, STRO and TECX.
When will Opaleye Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Opaleye Management's portfolio worth?
The Q2 2026 filing reports $1.1B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.